Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan plus toripalimab as neoadjuvant therapy for triple-negative breast cancer (phase II, single-arm)
ChiCTR2600116626Phase 2Not yet recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and toripalimab in triple-negative breast cancer (TNBC), sponsored by Jiangxi Cancer Hospital. Primary endpoint: Pathological complete remission rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecantoripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600116626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116626.